Opendata, web and dolomites


The First Cell Culture Platform that Enables Affordable Cell Therapies at a Large Scale

Total Cost €


EC-Contrib. €






 Facer project word cloud

Explore the words cloud of the Facer project. It provides you a very rough idea of what is the project "Facer" about.

few    quantity    barriers    trl    thanks    competitor    nowadays    surpass    treating    launching    patented    affordable    marking    validation    market    medical    starting    perform    human    injected    platform    describe    patients    august    approved    intervention    quantities    millions    expand    small    distributor    customer    modified    globally    500    commercially    curing    device    diabetes    culturing    biopsy    suffer    36    innovation    manufacture    overcome    life    ebitda    initially    once    afford    investments    external    cancer    facer    performances    centres    possibly    first    principles    shown    infrastructure    tackle    therapies    lower    deemed    tissue    incurable    culture    sale    cells    2018    cell    asks    iterative    autonomous    2024    turnover    quality    blood    cash    scalable    finalise    local    therapy    specialised    conclude    hinders    approval    million    diseases    gain    ce    treatments    successfully    course    regulatory    billions    superior   

Project "Facer" data sheet

The following table provides information about the project.


Organization address
postcode: SG1 2FX
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 2˙051˙000 €
 EC max contribution 1˙435˙700 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-04-01   to  2020-09-30


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    AGLARIS LIMITED UK (STEVENAGE) coordinator 1˙435˙700.00


 Project objective

Cell therapy has shown promising results for treating and curing a large range of diseases, from cancer to diabetes. The principles of cell therapy are easy to describe: cells (possibly modified) are injected into patients. Cell therapy is now a reality in Europe: in August 2018 the first two treatments for patients with blood cancer were approved; more of them are about to successfully conclude the approval path. What hinders the large-scale uptake of cell therapy is its costs: culturing enough cells of high quality requires specialised personnel and infrastructure, which only a few centres can afford. The market asks for a scalable cell culture platform that can produce large quantities of high quality cells at much lower costs than done nowadays. To address this need, we have developed the Facer – the first fully-autonomous cell culture platform. The Facer can manufacture billions of high-quality cells starting from the small quantity (about 500,000 cells) of a tissue biopsy without the need of human intervention, thanks to a unique patented iterative process. Our product is at TRL 7; its performances, in terms of quality and costs, are superior to any competitor commercially available. We have developed the Facer over the course of 5 years thanks to cash investments of over €3 million. In the Phase 2 project we will finalise the product, perform a validation with external partners, gain the CE marking (our product is not a medical device), and find a distributor and a launching customer. We will initially tackle the European market to then expand globally once that the local regulatory barriers are overcome. In 2024, after 5 years from the first sale, our turnover will surpass the €60 million and our EBITDA will be over €36 million. Our innovation can enable affordable cell therapies at a large scale and change the life of millions of patients who suffer from diseases that have been deemed 'incurable' so far.


year authors and title journal last update
List of publications.
2019 Mireia Ruiz
Development of an autonomous platform for CAR T-cell manufacturing
published pages: , ISSN: , DOI:
National Instrument case – Real world applications 2020-04-15

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "FACER" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "FACER" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

MCBD (2019)


Read More  

Plasmanorg (2019)

Environmental-friendly organic chemical synthesis in plasma reactor

Read More  

In-Heal (2019)

Standardised administration device for raw medical herbs

Read More